Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Post Menopausal Osteoporosis-Pipeline Review, H1 2015

Post Menopausal Osteoporosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Post Menopausal Osteoporosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Post Menopausal Osteoporosis-Pipeline Review, H1 2015', provides an overview of the Post Menopausal Osteoporosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Post Menopausal Osteoporosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Post Menopausal Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Post Menopausal Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Post Menopausal Osteoporosis Overview 8

Therapeutics Development 9

Pipeline Products for Post Menopausal Osteoporosis-Overview 9

Pipeline Products for Post Menopausal Osteoporosis-Comparative Analysis 10

Post Menopausal Osteoporosis-Therapeutics under Development by Companies 11

Post Menopausal Osteoporosis-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Post Menopausal Osteoporosis-Products under Development by Companies 15

Post Menopausal Osteoporosis-Companies Involved in Therapeutics Development 16

Amgen Inc. 16

Chronos Therapeutics Limited 17

Eli Lilly and Company 18

Hanmi Pharmaceuticals, Co. Ltd. 19

Merck & Co., Inc. 20

Oncobiologics, Inc. 21

Paras Biopharmaceuticals Finland Oy 22

Pfizer Inc. 23

Radius Health, Inc. 24

Unigene Laboratories, Inc. 25

Post Menopausal Osteoporosis-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

(aceclofenac + eperisone)-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

abaloparatide-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

bazedoxifene acetate-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

blosozumab-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

calcitonin-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

denosumab-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

denosumab biosimilar-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Drugs for Postmenopausal Osteoporosis-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

odanacatib-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

RDC-5-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

romosozumab-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

teriparatide biosimilar-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Post Menopausal Osteoporosis-Recent Pipeline Updates 56

Post Menopausal Osteoporosis-Dormant Projects 70

Post Menopausal Osteoporosis-Discontinued Products 71

Post Menopausal Osteoporosis-Product Development Milestones 72

Featured News & Press Releases 72

Jan 29, 2015: Radius Health Announces Oral Presentation of the ACTIVE Phase 3 Clinical Trial of Abaloparatide-SC for Postmenopausal Women With Osteoporosis at ICE/ENDO 2015 72

Dec 21, 2014: Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis 73

Nov 24, 2014: The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase II Study of the Investigational Drug Abaloparatide in Postmenopausal Women With Osteoporosis 74

Sep 15, 2014: Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis 75

Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis 77

Sep 15, 2014: New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 79

Aug 13, 2014: Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director 81

Jan 09, 2014: Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058) for Postmenopausal Osteoporosis Using Two Delivery Systems 81

Jan 02, 2014: Romosozumab phase 2 data published in New England Journal of Medicine show significant increases in bone mineral density at both spine and hip 83

Dec 31, 2013: Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Tables

Number of Products under Development for Post Menopausal Osteoporosis, H1 2015 9

Number of Products under Development for Post Menopausal Osteoporosis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Post Menopausal Osteoporosis-Pipeline by Amgen Inc., H1 2015 16

Post Menopausal Osteoporosis-Pipeline by Chronos Therapeutics Limited, H1 2015 17

Post Menopausal Osteoporosis-Pipeline by Eli Lilly and Company, H1 2015 18

Post Menopausal Osteoporosis-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 19

Post Menopausal Osteoporosis-Pipeline by Merck & Co., Inc., H1 2015 20

Post Menopausal Osteoporosis-Pipeline by Oncobiologics, Inc., H1 2015 21

Post Menopausal Osteoporosis-Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015 22

Post Menopausal Osteoporosis-Pipeline by Pfizer Inc., H1 2015 23

Post Menopausal Osteoporosis-Pipeline by Radius Health, Inc., H1 2015 24

Post Menopausal Osteoporosis-Pipeline by Unigene Laboratories, Inc., H1 2015 25

Assessment by Monotherapy Products, H1 2015 26

Assessment by Combination Products, H1 2015 27

Number of Products by Stage and Target, H1 2015 29

Number of Products by Stage and Mechanism of Action, H1 2015 31

Number of Products by Stage and Route of Administration, H1 2015 33

Number of Products by Stage and Molecule Type, H1 2015 35

Post Menopausal Osteoporosis Therapeutics-Recent Pipeline Updates, H1 2015 56

Post Menopausal Osteoporosis-Dormant Projects, H1 2015 70

Post Menopausal Osteoporosis-Discontinued Products, H1 2015 71

List of Figures

Number of Products under Development for Post Menopausal Osteoporosis, H1 2015 9

Number of Products under Development for Post Menopausal Osteoporosis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Top 10 Targets, H1 2015 28

Number of Products by Stage and Top 10 Targets, H1 2015 29

Number of Products by Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 31

Number of Products by Top 10 Routes of Administration, H1 2015 32

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 33

Number of Products by Top 10 Molecule Types, H1 2015 34

Number of Products by Stage and Top 10 Molecule Types, H1 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Chronos Therapeutics Limited

Eli Lilly and Company

Hanmi Pharmaceuticals, Co. Ltd.

Merck & Co., Inc.

Oncobiologics, Inc.

Paras Biopharmaceuticals Finland Oy

Pfizer Inc.

Radius Health, Inc.

Unigene Laboratories, Inc.

Post Menopausal Osteoporosis Therapeutic Products under Development, Key Players in Post Menopausal Osteoporosis Therapeutics, Post Menopausal Osteoporosis Pipeline Overview, Post Menopausal Osteoporosis Pipeline, Post Menopausal Osteoporosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com